Czechia· CZ-0238787
POLIVY
A polatuzumab vedotin product containing polatuzumab vedotin, registered in Czechia by Roche Registration GmbH, Grenzach-Wyhlen. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Polatuzumab vedotin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX14 (polatuzumab vedotin), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Polatuzumab vedotin · ATC L01FX14
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of polatuzumab vedotin costs, country by country.
Normalised to the WHO defined daily dose (6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Polatuzumab vedotin · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$513.20
The record
At a glance
SÚKL (Czech Republic)- Active substance
- POLATUZUMAB VEDOTIN
- Manufacturer
- Roche Registration GmbH, Grenzach-Wyhlen
- Country
- Czechia (CZ)
- ATC code
- L01FX14
- ATC class
- Polatuzumab vedotin
- Defined daily dose
- 6 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02387871CZK 262573.45
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
177 interactions on record for polatuzumab vedotin.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Polatuzumab vedotin · interactions on record
177 records
- 37 severe
- 137 moderate
- 3 minor
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Polatuzumab vedotin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayPolivyOrifarm AS
- FinlandPolivyOrifarm Oy
- SpainPOLIVY 140 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- IrelandPolivy 140 mg powder for concentrate for solution for infusionRoche Registration GmbH
- IcelandPolivyRoche Registration GmbH*
- PolandPolivyRoche Registration GmbH
- BelgiumPolivy 140 mgRoche Registration
- SwedenPolivy 140 mg Pulver till koncentrat till infusionsvätska, lösningRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Polivy
- Liechtenstein · Polivy
- Norway · Polivy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e5b8deb0-8afd-4de3-80bf-144a2f594cb8 GET /v1/drugs/e5b8deb0-8afd-4de3-80bf-144a2f594cb8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF PLV CSL",
"source": "sukl",
"strength": "140MG",
"pack_size": "1",
"substance": "POLATUZUMAB VEDOTIN",
"cz_kod_sukl": "0238787",
"product_type": "BT",
"substance_codes": "22071",
"registration_state": "R",
"registration_number": "EU/1/19/1388/001"
}See everything about polatuzumab vedotin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.